Pricing Log in Create free account

Korsana Biosciences, Inc. (KRSA) vs Taysha Gene Therapies, Inc. (TSHA)

Korsana Biosciences, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. Korsana Biosciences, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.4B and $1.3B). Taysha Gene Therapies, Inc. grew revenue faster over the last twelve months: 19.0% against −28.8%. Across the 13 metrics below, Taysha Gene Therapies, Inc. leads on 7 and Korsana Biosciences, Inc. on 6.

Valuation

Metric KRSA TSHA Biotechnology median
P/E n/m n/m 10.60
P/S 9.01 136.10 9.40
P/B 3.67 4.15 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 8.34 101.67 9.02
Earnings yield (38.12%) (9.66%) (32.88%)
Free cash flow yield (24.20%) (8.66%) (23.13%)

Profitability

Metric KRSA TSHA Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (98.22%) (47.05%) (51.96%)
Return on assets (82.29%) (37.23%) (46.06%)
Return on invested capital (115.40%) 0.00% 0.00%

Growth

Metric KRSA TSHA Biotechnology median
Revenue growth (TTM) (28.83%) 18.96% 6.76%
EPS growth (last fiscal year) 8.26% 5.56% 29.88%
Revenue growth, 5-year CAGR (14.38%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KRSA TSHA Biotechnology median
Debt to equity 0.00 0.13 0.00
Current ratio 0.82 17.76 4.97
Net debt to EBITDA 0.65 2.47 1.01

Dividend

Metric KRSA TSHA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KRSA TSHA Biotechnology median
Market cap 1.39b 1.33b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack